Review of Three FTSE All-Share Companies - Midatech Pharma Plc, Provexis Plc & Physiomics Plc

Midatech Pharma Plc

Midatech Pharma Plc (LON:MTPH) is a pharmaceutical company that develops and commercialises products in oncology and other therapeutic areas. The company’s products include oravig, zuplenz, soltamox and gelclair. Midatech’s products are used in the treatment of diabetes; rare cancers including brain, ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions. It collaborates with universities, and speciality and major pharmaceutical companies to develop its platform technologies.

The company’s stocks have their listing at the London Stock Exchange on the Alternative Investment Market (AIM) segment. There these shares trade under the ticker name MTPH, the shares of the company also form part of the AIM All-share index of the London Stock Exchange.

Trading Update

The company on 5 December 2019 came out with an update on the grant it has received worth €2.6 million from the European Union.

The grant has been received for the clinical trial of its compound MTX110, which is used in the treatment for Diffuse Intrinsic Pontine Glioma, a rare form of childhood brain cancer type.

Stock Performance at the London Stock Exchange

Source – Thomson Reuters

At the time of writing of this report at 10.27 AM GMT on 27 December 2019 the shares of the company were trading on the London Stock Exchange at GBX 2.535.

The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 13.88, while also registering a 52-week low of GBX 2.00, the company has a market capitalisation of £13.15 million on the London Stock Exchange at the time of writing this report on 27 December 2019.

The stock’s average traded volume as on the above date and time stood at 1,217,810 and the stock's average traded volume for 5 days was 1,111,393.60; 30 days- 952,402.73 and 90 days – 504,655.93 and the beta of the stock of the company on the date was 1.22, which compared to the benchmark index reflected a higher volatility and the stocks trading volumes on the London Stock Exchange on an average for 5 days was up by +16.69% as compared to the 30 days’ average traded volume and in the last one month, the shares have generated a return of -8.20% and also a return of -52.64 % on year to date basis.

Outlook

MTX110 is a unique drug that is used in the treatment for Diffuse Intrinsic Pontine Glioma which is a rare form of Brain cancer with very limited radiotherapeutic treatment available, which at most elongates the life of the patient by a few months. The treatment offered by the company if comes out successful in clinical trials will provide relief to numerous patients who are currently are devoid of any effective treatment.

Â

Provexis Plc

Provexis Plc (LON:PXS) is the United Kingdom domiciled speciality foods and wellness company. Its business is centred around a product by the brand name FruitFlow, which is based on a compound extracted from tomatoes and which inhibits platelet aggregation in the human body, platelet aggregation being one of the primary reasons for heart related ailments like heart attack, stroke and venous thrombosis. The company makes this product available in both syrup and powder form, which is used in various foods and beverages available through its licensee companies. The company on its own offers a dietary supplement called FruitFlow+ Omega-3 which is available through its e-commerce portal.

The company’s stocks have their listing at the London Stock Exchange on the Alternative Investment Market (AIM) segment. There these shares trade under the ticker name PXS, the shares of the company also form part of the AIM All-share index of the London Stock Exchange.

News Update

The company on 11 December 2019 came out with an update on the placement of fresh shares and raising of £0.301 million by the placing.

• A total of 75,333,333 new ordinary shares of the company of 0.1 pence each have been issued to new and existing investors as part of this exercise.
• The placement of the shares is conditional on their listing on the Alternative Investment Market (AIM) segment of the London Stock Exchange, for which an application has been made by the company. The shares have been placed 0.40 pence per share which represents a discount of 11.1 per cent to the closing mid-day price per ordinary share as on 10 December 2019.

Stock Performance at the London Stock Exchange

Source – Thomson Reuters

At the time of writing of this report at 11.53 AM GMT on 27 December 2019 the shares of the company were trading on the London Stock Exchange at GBX 0.683.

The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 0.78, while also registering a 52-week low of GBX 0.20, the company has a market capitalisation of £ 14.40 million on the London Stock Exchange at the time of writing this report on 27 December 2019.

The stock’s average traded volume as on the above date and time stood at 515,457, and the stock's average traded volume for 5 days was 9,303,312.00; 30 days- 4,072,520.53 and 90 days – 2,443,553.78 and the beta of the stock of the company on the date was 0.10, which compared to the benchmark index reflected a lower volatility. The stocks trading volumes on the London Stock Exchange on an average for 5 days was up by +128.44% as compared to the 30 days’ average traded volume, and in last one month, the shares have generated a return of +64.71% and also a return of +180.00% on year to date basis.

Physiomics Plc

Physiomics Plc (LON:PYC) aims to develop breakthrough achievements in the field of cancer by transforming oncology drug development which can be applied in the real world. The company uses its proprietary technology known as Virtual TumourTM technology and related tools to track, predict and research various treatments of cancer. The company helps other cancer development players by partnering with them in both pre-clinical and clinical development and excel by knowledge sharing, using mathematical models. The company is flexible in its approach and open to discussions in order to customise if required. In addition, the company provides consultants who have distinct experience in working for big clients, small clients and not-for-profit clients

The company’s stocks have their listing at the London Stock Exchange on the Alternative Investment Market (AIM) segment. There these shares trade under the ticker name PYC, the shares of the company also form part of the AIM All-share index of the London Stock Exchange.

News Update

On 20 December 2019, the company came out with an update that in furtherance to its business arrangement with Merck KGaA. The two companies have agreed for an early tranche of projects for the year 2020 having a total value of GBP 250,000. The present arrangement with Merck KGaA came into being on 28 November 2017.

Stock Performance at the London Stock Exchange

Source – Thomson Reuters

At the time of writing of this report at 11.54 AM GMT on 27 December 2019 the shares of the company were trading on the London Stock Exchange at GBX 3.36.

The shares of the company during the past 52 weeks of trading at the London Stock Exchange have registered a 52-week high of GBX 4.634, while also registering a 52-week low of GBX 2.22, the company has a market capitalisation of £2.41 million on the London Stock Exchange at the time of writing this report on 27 December 2019.

The stock’s average traded volume as on the above date and time stood at 403,016, and the stock's average traded volume for 5 days was 1,427,702.60; 30 days- 450,244.57 and 90 days – 347,422.83 and the beta of the stock of the company on the date was -6.94, which compared to the benchmark index reflected a higher volatility in the inverse direction. The stocks trading volumes on the London Stock Exchange on an average for 5 days was up by +217.09 % as compared to the 30 days’ average traded volume and in last one month, the shares have generated a return of +28.85 % and also a return of -11.84 % return on year to date basis.

Outlook

The business arrangement with Merck KGaA provides for contract research done by the company on the client’s behalf. The projects are expected to be completed in the first six to eight months of the next financial year and the revenue recognition for the same if the schedule is kept, will the same as the present year.